First Trust Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $341M | Buy |
547,132
+200,277
| +58% | +$136M | 0.2% | 113 |
|
|
2026
Q1 | $268M | Buy |
346,855
+141,123
| +69% | +$108M | 0.19% | 130 |
|
|
2025
Q4 | $159M | Buy |
205,732
+7,475
| +4% | +$5.08M | 0.12% | 213 |
|
|
2025
Q3 | $111M | Buy |
198,257
+14,213
| +8% | +$8.04M | 0.08% | 292 |
|
|
2025
Q2 | $96.6M | Buy |
184,044
+70,124
| +62% | +$39.1M | 0.08% | 312 |
|
|
2025
Q1 | $72.3M | Sell |
113,920
-158,672
| -58% | -$109M | 0.06% | 392 |
|
|
2024
Q4 | $194M | Sell |
272,592
-19,349
| -7% | -$16.2M | 0.17% | 155 |
|
|
2024
Q3 | $307M | Sell |
291,941
-70,364
| -19% | -$78.3M | 0.29% | 76 |
|
|
2024
Q2 | $381M | Buy |
362,305
+25,833
| +8% | +$25M | 0.39% | 40 |
|
|
2024
Q1 | $324M | Sell |
336,472
-29,478
| -8% | -$28M | 0.33% | 53 |
|
|
2023
Q4 | $321M | Buy |
365,950
+195,902
| +115% | +$161M | 0.35% | 44 |
|
|
2023
Q3 | $140M | Buy |
170,048
+8,430
| +5% | +$6.63M | 0.17% | 165 |
|
|
2023
Q2 | $116M | Sell |
161,618
-62,057
| -28% | -$47.8M | 0.13% | 192 |
|
|
2023
Q1 | $184M | Buy |
223,675
+23,995
| +12% | +$18.1M | 0.21% | 128 |
|
|
2022
Q4 | $144M | Sell |
199,680
-253,607
| -56% | -$187M | 0.17% | 163 |
|
|
2022
Q3 | $312M | Buy |
453,287
+54,716
| +14% | +$34.4M | 0.4% | 28 |
|
|
2022
Q2 | $236M | Buy |
398,571
+225,696
| +131% | +$147M | 0.29% | 77 |
|
|
2022
Q1 | $121M | Sell |
172,875
-30,812
| -15% | -$19.5M | 0.12% | 206 |
|
|
2021
Q4 | $129M | Buy |
203,687
+5,969
| +3% | +$3.67M | 0.13% | 197 |
|
|
2021
Q3 | $120M | Buy |
197,718
+25,468
| +15% | +$15.8M | 0.13% | 203 |
|
|
2021
Q2 | $96.2M | Sell |
172,250
-1,807
| -1% | -$915K | 0.1% | 248 |
|
|
2021
Q1 | $82.4M | Buy |
174,057
+12,136
| +7% | +$5.91M | 0.1% | 262 |
|
|
2020
Q4 | $78.2M | Sell |
161,921
-202,221
| -56% | -$109M | 0.1% | 254 |
|
|
2020
Q3 | $204M | Buy |
364,142
+5,081
| +1% | +$3.08M | 0.33% | 60 |
|
|
2020
Q2 | $224M | Buy |
359,061
+108,792
| +43% | +$61.8M | 0.39% | 38 |
|
|
2020
Q1 | $122M | Sell |
250,269
-56,285
| -18% | -$23.2M | 0.28% | 62 |
|
|
2019
Q4 | $115M | Buy |
306,554
+10,321
| +3% | +$3.47M | 0.2% | 106 |
|
|
2019
Q3 | $82.2M | Sell |
296,233
-50,727
| -15% | -$15M | 0.15% | 161 |
|
|
2019
Q2 | $109M | Sell |
346,960
-13,602
| -4% | -$4.53M | 0.2% | 107 |
|
|
2019
Q1 | $148M | Buy |
360,562
+69,493
| +24% | +$28.6M | 0.29% | 53 |
|
|
2018
Q4 | $109M | Buy |
291,069
+2,589
| +0.9% | +$948K | 0.26% | 66 |
|
|
2018
Q3 | $117M | Buy |
288,480
+100,492
| +53% | +$38.2M | 0.22% | 88 |
|
|
2018
Q2 | $64.9M | Buy |
187,988
+39,879
| +27% | +$12.5M | 0.13% | 152 |
|
|
2018
Q1 | $51M | Buy |
148,109
+26,584
| +22% | +$9.25M | 0.12% | 187 |
|
|
2017
Q4 | $45.7M | Sell |
121,525
-27,786
| -19% | -$11.3M | 0.11% | 217 |
|
|
2017
Q3 | $66.8M | Buy |
149,311
+38,887
| +35% | +$18.5M | 0.17% | 123 |
|
|
2017
Q2 | $54.2M | Buy |
110,424
+16,638
| +18% | +$7.28M | 0.14% | 153 |
|
|
2017
Q1 | $36.3M | Sell |
93,786
-30,070
| -24% | -$11.1M | 0.1% | 236 |
|
|
2016
Q4 | $45.5M | Buy |
123,856
+37,666
| +44% | +$14.3M | 0.14% | 154 |
|
|
2016
Q3 | $34.6M | Sell |
86,190
-710
| -0.8% | -$285K | 0.1% | 225 |
|
|
2016
Q2 | $30.3M | Sell |
86,900
-74,579
| -46% | -$28.7M | 0.1% | 253 |
|
|
2016
Q1 | $58.2M | Sell |
161,479
-200,942
| -55% | -$82.8M | 0.19% | 107 |
|
|
2015
Q4 | $197M | Sell |
362,421
-63,792
| -15% | -$34.6M | 0.51% | 16 |
|
|
2015
Q3 | $198M | Sell |
426,213
-39,477
| -8% | -$21.2M | 0.57% | 13 |
|
|
2015
Q2 | $238M | Buy |
465,690
+1,993
| +0.4% | +$973K | 0.62% | 10 |
|
|
2015
Q1 | $209M | Buy |
463,697
+133,151
| +40% | +$56.4M | 0.61% | 12 |
|
|
2014
Q4 | $136M | Buy |
330,546
+88,944
| +37% | +$35M | 0.46% | 14 |
|
|
2014
Q3 | $87.1M | Sell |
241,602
-40,852
| -14% | -$13.7M | 0.34% | 36 |
|
|
2014
Q2 | $79.8M | Buy |
282,454
+25,981
| +10% | +$7.7M | 0.33% | 31 |
|
|
2014
Q1 | $77M | Sell |
256,473
-29,241
| -10% | -$9.01M | 0.34% | 35 |
|
|
2013
Q4 | $78.6M | Sell |
285,714
-6,636
| -2% | -$1.91M | 0.38% | 22 |
|
|
2013
Q3 | $91.5M | Buy |
292,350
+100,513
| +52% | +$26.4M | 0.5% | 12 |
|
|
2013
Q2 | $43.1M | Buy |
+191,837
| New | +$44.7M | 0.28% | 53 |
|
Other funds holding REGN
VCM
VPM
N
First Trust Advisors's REGN Position: Q2 2026 in Review
First Trust Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 58% in Q2 2026, buying an estimated $136M and bringing the position to 547,132 shares worth $341M. The position accounts for 0.2% of the portfolio, ranked #113.
First Trust Advisors first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $381M in Q2 2024. 1,085 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- First Trust Advisors held 547,132 shares of Regeneron Pharmaceuticals worth $341M as of Q2 2026.
- First Trust Advisors bought 200,277 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $136M.
- Regeneron Pharmaceuticals made up 0.2% of First Trust Advisors's portfolio in Q2 2026, its #113 holding.
- First Trust Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- First Trust Advisors's Regeneron Pharmaceuticals position peaked at $381M in Q2 2024.
- 1,085 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.